

## SPCG report

Since the latest NUF meeting the SPCG group have been initiating one randomized new study on different surveillance strategies in men on active surveillance – SPCG17. The study lead by Anna Bill-Axelsson, Sweden is primarily recruiting in Sweden, whereas the other member countries are in the process on initiating the study. The SPCG-15 study was as of January 2019 reached half way in the recruitment process with app. 600 men with locally advanced prostate cancer recruited for either standard treatment combined radiation and endocrine therapy, compared to surgery and subsequent radiation if primary treatment fails. If recruitment continues with the current pace, the last patient is expected to enter study in 2023, this may, however, change as other centers out-side Scandinavia have expressed interest in future collaboration.

Future publication are planned including a long-term follow-up on the ADPRO study, and new studies are being planned.

At the latest board meeting Jan 2019, Göran Ahlgren, Malmö resigned as chairman following 8 years of service, and was replaced by Klaus Brasso, Copenhagen. The SPCG board wishes to express their deep gratitude to Göran Ahlgren for his long-term devoting to the SPCG.

## Publications 2017-19

1. Ahlgren GM, Flodgren P, Tammela TLJ, Kellokumpu-Lehtinen P, Borre M, Angelsen A, Iversen JR, Sverrisdottir A, Jonsson E, Sengelov L; Investigators of the Scandinavian Prostate Cancer Study Number 12. Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial. *Eur Urol.* 2018 Jun;73(6):870-876
2. Cazzaniga W, Garmo H, Robinson D, Holmberg L, Bill-Axelsson A, Stattin P. Mortality after radical prostatectomy in a matched contemporary cohort in Sweden compared to the Scandinavian Prostate Cancer Group 4 (SPCG-4) study. *BJU Int.* 2018 Sep 25. doi: 10.1111/bju.14563. [Epub ahead of print]
3. Ebbinge M, Berglund A, Varenhorst E, Hedlund PO, Sandblom G; Scandinavian Prostate Cancer Group (SPCG)-5 Study Group. Clinical and prognostic significance of changes in haemoglobin concentration during 1 year of androgen-deprivation therapy for hormone-naïve bone-metastatic prostate cancer. *BJU Int.* 2018 Oct;122(4):583-591
4. Stranne J, Brasso K, Brennhovd B, Johansson E, Jäderling F, Kouri M, Lilleby W, Meidahl Petersen P, Mirtti T, Pettersson A, Rannikko A, Thellenberg C, Akre O. SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. *Scand J Urol.* 2018 Dec 26:1-8. doi: 10.1080/21681805.2018.1520295. [Epub ahead of print]
5. Wedde TB, Småstuen MC, Brabrand S, Fosså SD, Kaasa S, Tafjord G, Russnes KM, Hellebust TP, Lilleby W. Ten-year survival after High-Dose-Rate Brachytherapy combined with External Beam Radiation Therapy in high-risk prostate cancer: A comparison with the Norwegian SPCG-7 cohort. *Radiother*

Oncol. 2018 Oct 30. pii: S0167-8140(18)33537-0. doi: 10.1016/j.radonc.2018.10.013. [Epub ahead of print]

6. Bill-Axelsson A, Holmberg L, Garmo H, Taari K, Busch C, Nordling S, Häggman M, Andersson SO, Andrén O, Steineck G, Adami HO, Johansson JE. Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up. N Engl J Med. 2018 Dec 13;379(24):2319-2329
7. Hedlund PO, Damber J-E, Hagerman I, Haukaas S, Henriksson P, Iversen P, Johansson R, Klarskov P, Lundbeck F, Rasmussen F, Varenhorst E, Vitanen J. Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer: Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5. Scand J Urol Nephrol 2018;42:220-229.
8. Bill-Axelsson A, Holmberg L, Filén F, Ruutu M, Garmo H, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Adami HO, Johansson JE; for the Scandinavian Prostate Cancer Group Study Number 4. Radical Prostatectomy Versus Watchful Waiting in Localized Prostate Cancer: the Scandinavian Prostate Cancer Group-4 Randomized Trial. J Natl Cancer Inst. 2008 Aug 11.

<b>Board</b>	<b>Mail</b>
Göran Ahlgren, urology SE/PI SPCG-12/SPCG Foundation 2004	spcg@outlook.com
Johan Stranne, urology SE/ Ordinary member/SPCG Foundation 2014	johan.stranne@vgregion.se
Camilla Thellenberg, oncology SE/ Ordinary member 2016	camilla.thellenberg@onkologi.umu.se
Helena Bertilsson, urology NO/Ordinary member 2017	helena.bertilsson@stolav.no
Erik Skaaheim Haug, urology NO/ Ordinary member 2017	erik.haug@siv.no
Andreas Stensvold, oncology NO/Ordinary member 2018	Andreas.stensvold@so-hf.no
Antti Rannikko, urology FI/Ordinary member 2019	Antti.Rannikko@hus.fi
Teemu Murtola, urology FI/ Ordinary member 2019	teemu.murtola@uta.fi
Petteri Hervonen, oncology FI/ Ordinary member 2018	petteri.hervonen@hus.fi
Klaus Brasso, urology DK/Chair/SPCG Foundation 2002, Chair 2019-	klausbrasso@hotmail.com
Mads Hvid Poulsen, urology DK/Ordinary member 2019	Mads.poulsen@rsyd.dk
Henriette Lindberg, oncology DK/Secretary 2012	henriette.lindberg@regionh.dk